Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Final intermediates

In striking contrast to the above observations is the finding that both reduction and reductive methylation of the tetrahydropyranyl ether of 17a-ace-toxypregnenolone (71) afford the expected products (72a, b) in 85-88 % yields by direct crystallization of the crude reaction products. Clearly, the complications in the reduction of the 16-en-20-one system are attributable primarily to reactions of the carbon-carbon double bond rather than to the a-carbanion (73), which is the final intermediate in both the reduction of the 16-dehydro compounds and the 17-acetoxy ketones. [Pg.40]

Finally, intermediate cationic allyl complexes of palladium15,16 and ruthenium17, produced from allylic esters by the action of substoichiometric amounts of the metal catalyst, have been electronically inverted by reduction to become nucleophilic anion equivalents, which are capable of carbonyl addition. [Pg.452]

C can then undergo further intersystem crossing to the T state, D. The final intermediate produced in the photodissociation of the synthetic hemes, D, has been shown to be, within experimental error, equivalent to the ground deoxy state. D correlates with the production of the quintet state, both directly from B and through further reaction of the deoxy state C. Therefore we assign D to... [Pg.198]

Zhang has proposed a mechanism for the rhodium-catalyzed Alder-ene reaction based on rhodium-catalyzed [4-1-2], [5-i-2], and Pauson-Khand reactions, which invoke the initial formation of a metallacyclopentene as the key intermediate (Scheme 8.1) [21]. Initially, the rhodium(I) species coordinates to the alkyne and olefin moieties forming intermediate I. This intermediate then undergoes an oxidative cycHzation forming the metallacyclopentene II, followed by a y9-hydride elimination to give the appending olefin shown in intermediate III. Finally, intermediate III undergoes reductive elimination to afford the 1,4-diene IV. [Pg.156]

A move to a different manufacturing site for the manufacture or processing of drug substance intermediates, other than the final intermediate. [Pg.527]

Any process change made after the final intermediate processing step in drug substance manufacture. [Pg.529]

A change in an analytical procedure used for testing components, packaging components, the final intermediate, in-process materials after the final intermediate, or starting materials introduced after the final Inter-... [Pg.532]

Final Intermediate The last compound synthesized before the reaction that produces the drug substance. The final step forming the drug substance must involve covalent bond formation or breakage ionic bond fonnation (i.e., making the salt of a compound) does not qualify. Consequently, when the drug substance is a salt, the precursors to the organic acid or base, rather than the acid or base itself, should be considered the final intermediate. [Pg.548]

Now I would like to turn to some of the issues of operations within the manufacturing process itself and speak to certain process controls that are expected. In a chemical synthesis sequence, as I mentioned above, intermediates will need to be fully characterized. That characterization will then lead to a set of specifications for the intermediate, that is, its level of purity, its form, etc. Test procedures that demonstrate that the intermediate meets specifications must be established. Some intermediates are deemed to be more important than others and are given specific designation, such as pivotal, key, and final intermediates. In those cases, it is necessary to demonstrate that the specific and appropriate structure is obtained from the chemical reaction and that the yield of the intermediate is documented and meets the expected yield to demonstrate process reproducibility and control. Purity of the substance is to be appropriately documented. And, finally, in reactions which produce pivotal, key, and final intermediates, side products or undesirable impurities are identified and their concentrations measured and reduced by appropriate purification procedures so that the intermediate meets in-process specifications. Thus, those important intermediates become focuses of the process to demonstrate that the process is "under control" and functioning in a reproducible and expected manner. All of these activities ultimately are designed to lead to the production of the actual active ingredient which is referred to then as a "bulk pharmaceutical agent." That final product will need to be completely characterized which then will document that it meets a set of specifications ("Final Product Specifications") for qualification as suitable for pharmaceutical use. [Pg.263]

Another important experiment398 showed that lsO from [2-lsO]propanediol was transferred into the 1 position without exchange with solvent. Furthermore, lsO from (S)-[l-lsO]propanediol was retained in the product while that from the (R) isomer was not. Thus, it appears that the enzyme stereospecifically dehydrates the final intermediate. From these and other experiments, it was concluded that initially a 5 -deoxyadenosyl radical is formed via Eq. 16-35. This radical then abstracts the hydrogen atom marked by a shaded box in Eq. 16-36 to form a substrate radical and 5 -deoxy-adenosine. One proposal, illustrated in Eq. 16-36, is that the substrate radical immediately recombines with... [Pg.872]

The reaction pathway and product distribution observed in the Re2(CO)io- and Rh6(CO)16-catalyzed autoxidation of cyclohexanol and cyclohexanone are shown in Scheme II. An important intermediate is the peracid. In this sequence the peracid is the final intermediate ... [Pg.294]

In most synthetic chemical reactions, the processes involved have been simplified. (See Fig. 2.) Process validation should be conducted for the final active drug moiety or API (A), the final intermediates (B and C), as well as the key intermediates (D and E) that produced B and the key intermediates (F and G) that produced C. Final product (A) and final intermediates (B and C) should... [Pg.408]

Theoretically, every unit operation conducted in the plant comes under the CGMP umbrella, and is therefore subject to the need for validation documentation requirements. This includes not only the final API but also the manufacture of the final intermediate(s) (or main reactants), key intermediates that are used to prepare the final intermediate(s), all the way back to commercial starting materials that enter the plant, as well as the pivotal intermediates thereafter. [Pg.409]

The level of control and validation documentation required (i.e., through increased testing and tighter specifications) increases as one moves closer, in a multistep, in-plant process, to the outcomes [i.e., final intermediate(s) and the API itself]. Naturally, when key and final intermediates are sourced from outside the company, they must enter with appropriate certificates of analysis (CofA), plus thorough inspections of off-site facilities by quality assurance personnel. [Pg.409]

Manufacturing process changes involving synthetic steps through the final intermediates... [Pg.432]

Changes to the final intermediates and the resulting API will be covered in the BACPAC II guidance document. Postapproval changes affecting peptides, oligonucleotides, radiopharmaceuticals, natural materials, and semisynthetic APIs are not covered by BACPAC at the present time. [Pg.432]

Cleaning validation protocols should describe the equipment to be cleaned, procedures, materials, acceptance criteria, parameters to be monitored and controlled, and the analytical methods to be employed for testing. Validation of cleaning procedures should reflect equipment to be used for key and final intermediates and APIs. The selection of cleaning procedures to be employed should be based on material solubility and cleaning difficulty. The calculation of residue limits should consider the potency, toxicity, and stability of critical materials. [Pg.435]

Hsueh, C.H., Evans, A.G. and Coble, R.L., Microstructure development during final/intermediate stage sintering -1. Pore/grain boundary separation , Acta. Metall., 1982 30 1269-1279. [Pg.306]

Conversion oflhx-HydroxylatedBetamethasone Intermediate into Betamethasone Alcohol in Puerto Rico. As indicated in the section entitled From Plant Saponins to 16 p-Methyl Intermediates, the most inefficient steps in processing the final intermediate from Mexico (i.e., XLI) into betamethasone alcohol were the steps to introduce the A911 double bond into XLI. The process sequence is outline in Scheme 11. [Pg.260]

By incorporating these formulae into the rate equation, starting with the final intermediate X , we find... [Pg.206]


See other pages where Final intermediates is mentioned: [Pg.70]    [Pg.359]    [Pg.523]    [Pg.281]    [Pg.365]    [Pg.206]    [Pg.188]    [Pg.200]    [Pg.128]    [Pg.23]    [Pg.52]    [Pg.527]    [Pg.530]    [Pg.533]    [Pg.534]    [Pg.534]    [Pg.95]    [Pg.415]    [Pg.409]    [Pg.431]    [Pg.432]    [Pg.432]    [Pg.768]    [Pg.298]    [Pg.733]    [Pg.259]    [Pg.136]    [Pg.238]    [Pg.127]    [Pg.246]   
See also in sourсe #XX -- [ Pg.15 ]




SEARCH



© 2024 chempedia.info